eMedicine Specialties > Pediatrics: General Medicine > Endocrinology

Precocious Puberty

Author: Paul B Kaplowitz, MD, PhD, Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center
Contributor Information and Disclosures

Updated: Jun 30, 2009

Introduction

Background

Precocious puberty refers to the appearance of physical and hormonal signs of pubertal development at an earlier age than is considered normal. For many years, puberty was considered precocious in girls younger than 8 years; however, recent studies indicate that signs of early puberty (breasts and pubic hair) are often present in girls (particularly black girls) aged 6-8 years. For boys, onset of puberty before age 9 years is considered precocious.

Early onset of puberty can cause several problems. The early growth spurt initially can cause tall stature, but rapid bone maturation can cause linear growth to cease too early and can result in short adult stature. The early appearance of breasts or menses in girls and increased libido in boys can cause emotional distress for some children. 

Premature pubarche and premature thelarche are 2 common, benign, normal variant conditions that can resemble precocious puberty but are nonprogressive or very slowly progressive. Premature thelarche refers to the isolated appearance of breast development, usually in girls younger than 3 years; premature pubarche refers to appearance of pubic hair without other signs of puberty in girls or boys younger than 7-8 years. A thorough history, physical examination, and growth curve review can help distinguish these normal variants from true sexual precocity.

If the history, physical examination, and laboratory data suggest that a child exhibits early and sustained evidence of pubertal maturation, the clinician must differentiate central precocious puberty (CPP) from precocious pseudopuberty. CPP, which is gonadotropin-dependent, is the early maturation of the entire hypothalamic-pituitary-gonadal (HPG) axis, with the full spectrum of physical and hormonal changes of puberty. Precocious pseudopuberty is much less common and refers to conditions in which increased production of sex steroids is gonadotropin-independent (see Precocious Pseudopuberty). Correct diagnosis of the etiology of sexual precocity is critical, because evaluation and treatment of patients with precocious pseudopuberty is quite different than that for patients with CPP.

Pathophysiology

Most patients, particularly girls suspected of having CPP, are otherwise healthy children whose pubertal maturation begins at the early end of the normal distribution curve. CNS imaging studies of these otherwise healthy 6-year-old to 8-year-old girls usually reveal no structural abnormalities. A 2002 study of 200 girls in France found abnormal brain imaging findings in 2% of girls whose onset of puberty was between age 6-8 years and in 20% of girls whose onset of puberty was before age 6 years.1 A smaller 2003 study from the United Kingdom reported abnormal findings in 15% of 67 girls.2 Abnormal CT scan or MRI findings are more frequent among boys with CPP than among girls with CPP.

The onset of puberty is caused by the secretion of high-amplitude pulses of gonadotropin-releasing hormone (GnRH) by the hypothalamus. The hypothesized mechanisms that suppress onset of puberty include (1) the HPG axis, which is highly sensitive to feedback inhibition by small amounts of sex steroids, and (2) central neural pathways that suppress the release of GnRH pulses.

CNS abnormalities associated with precocious puberty include the following:

  • Tumors (eg, astrocytomas, gliomas, germ cell tumors secreting human chorionic gonadotropin [HCG])
  • Hypothalamic hamartomas
  • Acquired CNS injury caused by inflammation, surgery, trauma, radiation therapy, or abscess
  • Congenital anomalies (eg, hydrocephalus, arachnoid cysts, suprasellar cysts)

High-amplitude pulses of GnRH cause pulsatile increases in the pituitary gonadotropin-luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Increased LH levels stimulate production of sex steroids by testicular Leydig cells or ovarian granulosa cells. Pubertal levels of androgens or estrogens cause the physical changes of puberty, including penile enlargement and sexual hair in boys and breast development in girls. These levels also mediate the pubertal growth spurt. Increased FSH levels cause enlargement of the gonads in both sexes and eventually promote follicular maturation in girls and spermatogenesis in boys.

Frequency

United States

The frequency of precocious puberty in girls and boys largely depends on the age at which the condition is considered precocious.

In 1969, Marshall and Tanner published the results of their study of 192 white British girls.3 These researchers stated that the average age of thelarche was 11 years and defined precocious puberty in girls as that which started before age 8 years. No studies that looked at the age of appearance of breast and pubic hair in normal children were performed in the United States during that same time. However, many in the United States had the impression that girls had been maturing earlier than in the past.

No data were available to confirm this impression until 1997, when Herman-Giddens et al reported on the incidence of breast and pubic hair development by age and race in 17,000 US girls aged 3-12 years.4 They used the established definition that breast or pubic development in girls was precocious before age 8 years and estimated that approximately 8% of white and 25% of black girls in the United States exhibited evidence of sexual precocity. The results of this study are illustrated in Media files 1-2.

Graph represents the prevalence of breast develop...

Graph represents the prevalence of breast development at Tanner stage 2 or greater by age and race.

Graph represents the prevalence of breast develop...

Graph represents the prevalence of breast development at Tanner stage 2 or greater by age and race.



Graph represents the prevalence of pubic hair at ...

Graph represents the prevalence of pubic hair at Tanner stage 2 or greater by age and race.

Graph represents the prevalence of pubic hair at ...

Graph represents the prevalence of pubic hair at Tanner stage 2 or greater by age and race.


In 1999, Kaplowitz and Oberfield published new guidelines recommending that puberty be considered precocious only when breast development or pubic hair appear before age 7 years in white girls and age 6 years in black girls.5 Based on these revised definitions and the 1997 data, an estimated 4-5% of girls from both racial groups are considered precocious in their pubertal maturation. Any child younger than age 8-9 years who demonstrates rapid pubertal progression or any girl who menstruates before age 9 years should be evaluated by a pediatric endocrinologist.

Reliable estimates of the frequency of precocious puberty in boys have not been published. However, several centers have reported that they evaluate between one fifth and one tenth as many boys as girls for sexual precocity.

International

A 2003 review of trends in timing of puberty around the world show no clear trend toward earlier puberty in northern Europe, but earlier mean age of menarche has been reported in some southern European countries and other warmer parts of the world.6 An interesting and still unexplained finding is the high incidence of precocious puberty in girls adopted into Western Europe from various underdeveloped countries.

Mortality/Morbidity

Isolated sexual precocity of unknown etiology carries no increased risk of mortality; however, distinguishing between children with idiopathic CPP and the rare patient with a CNS, adrenal, or ovarian tumor is important because the latter group may be at risk for tumor-related complications. Some, but not all, studies have found an association between early puberty in girls and a higher risk of breast cancer.

Children with precocious puberty may be stressed because of physical and hormonal changes they are too young to understand. They may be teased by their peers because of their physical difference. Girls who reach menarche before age 9-10 may become withdrawn and may have difficulty adjusting to wearing and changing pads. Both sexes, but more so boys than girls, may have increases in libido leading to increased masturbation or inappropriate sexual behaviors at a young age. Girls with a history of early puberty have a slightly earlier age of initiation of sexual activity.

Some studies have found that children with precocious puberty more frequently exhibit behavioral problems and are less socially competent than age-matched peers. Some, but not all, studies find evidence of emotional problems persisting into adulthood. The distress associated with early menses can be decreased if parents are encouraged to prepare their daughters for this event when they reach stage III-IV of breast development.

Early puberty accelerates growth. These children may initially be considerably taller than their peers. Because bone maturation is also accelerated, growth may be completed at an unusually early age, resulting in short stature. Short stature is more likely if puberty starts very early (ie, before age 6 y) than if it begins moderately early (ie, ages 6-8 y). Several studies show that most untreated girls with idiopathic CPP reach an adult height within the reference range. Determination of bone age can be used to predict adult height and to select patients with high risk for short stature if left untreated.

Race

The 1997 study by Herman-Giddens et al and the data from the National Health and Nutrition Examination Survey (NHANES) III study conducted from 1988-1994 show conclusively showed that black girls in the United States have onset of breast development and pubic hair about one year earlier than white girls; thus using the same age definition of precocious puberty for white and black girls yields a higher incidence in black girls (see Media files 1-2).4,7 No current evidence shows that black boys mature earlier than white boys; thus, incidence of precocious puberty among boys is similar in both races. The NHANES III study indicated that Mexican-American girls start breast development at a similar age as white girls, and that pubic hair appears slightly later.7

Sex

In a series of more than 200 patients evaluated at a single medical center, CPP occurred 5 times more often in girls than boys.8 Idiopathic CPP occurred 8 times more often. A possible explanation for this difference is that many girls whose puberty is considered precocious are actually healthy girls at the early end of the normal distribution.

Age

If precocious puberty in females (mostly central) is defined as the early onset of breast development, then the data of Herman-Giddens et al (Media file 1) can be used to estimate frequency of CPP at different ages in both white girls and black girls. Be cautious, however, in equating breast development in 3-year-olds with CPP because most such girls actually have premature thelarche, a benign normal variant (see Differentials). The younger the age of girls with proven CPP, the higher the likelihood of serious underlying disorder.

Clinical

History

  • Precocious puberty in girls
    • The first and most obvious sign of early puberty is usually breast enlargement, which may initially be unilateral.
    • Pubic and axillary hair may appear before, at about the same time, or well after the appearance of breast tissue. Axillary odor usually starts about the same time as the appearance of pubic hair.
    • Menarche is a late event and does not usually occur until 2-3 years after onset of breast enlargement.
    • The pubertal growth spurt occurs early in female puberty and usually appears by the time of initial evaluation.
  • Precocious puberty in boys
    • The earliest evidence of puberty is testicular enlargement, a subtle finding that often goes unnoticed by patients and parents.
    • Growth of the penis and scrotum and appearance of pubic hair typically occur at least a year after testicular enlargement.
    • Accelerated linear growth (the pubertal growth spurt) occurs later in the course of male puberty than in female puberty but often occurs by the time other physical changes are noted.

Physical

  • Precocious puberty in girls
    • The most reliable sign of increased estrogen production is breast enlargement. Initially, breast budding may be unilateral or asymmetric. Gradually, the breast diameter increases, the areola darkens and thickens, and the nipple becomes more prominent. Distinguishing glandular breast tissue from fat, which can mimic true breast tissue, is essential. Examining the patient while she is in the supine position usually minimizes the chance of misinterpreting fat as true breast enlargement.
    • Genital examination may or may not reveal pubic hair, but enlargement of the clitoris indicates significant androgen excess that must be promptly evaluated. The vaginal mucosa, which is a deep-red color in prepubertal girls, takes on a moist pastel-pink appearance as estrogen exposure increases.
    • Mild acne may be normal in early puberty, but rapid onset of severe acne, like clitoral enlargement, should increase suspicion of an androgen-excess disorder.
  • Precocious puberty in boys
    • The earliest sign of central precocious puberty (CPP) is enlargement of the testes, which depends on increased production of follicle-stimulating hormone (FSH); testicular length is more than 2.5 cm or testicular volume (with Prader orchidometer beads) is more than 4 mL. If progressive signs of androgen excess occur in a boy without increased testicular size, consider possible causes of precocious pseudopuberty, including congenital adrenal hyperplasia, familial male precocious puberty, and Leydig-cell tumors (a testicular nodule is usually palpable). Human chorionic gonadotropin (HCG)-secreting tumors somewhat increase testicular size by stimulating testicular Leydig-cell LH receptors.
    • Other signs of puberty (eg, penis growth, reddening and thinning of the scrotum, increased pubic hair) are a consequence of increased testosterone production and occur within 1-2 years after testicular enlargement.
    • Pubic hair growth that occurs without penis and testicular enlargement and other signs of increased androgen production usually reflects increased adrenal androgen production (ie, premature adrenarche) rather than true puberty.
    • Later signs of puberty include the pubertal growth spurt, acne, voice change, and facial hair.

Causes

  • Genetics: The timing of puberty has a genetic component. A history of early puberty in a parent or sibling is relevant and decreases the likelihood that early puberty has an organic cause. One study from Israel estimated that precocious puberty was familial in one fourth of cases and that the predominant mode of inheritance was autosomal dominant.9
  • Body fat
    • An increased body mass index (BMI) has been associated with early puberty.10 In some studies the association is stronger in white girls than in black girls. Obesity is not clearly associated with early puberty in boys.
    • In the 1970s, Frisch et al proposed that girls need a certain weight or body fat content to trigger menarche and to maintain cyclical menses.11 The relationship between body fat and puberty is complex and has many exceptions; however, body weight and fat mass are clearly among the factors that may influence puberty onset in girls.
    • A recent longitudinal study of 354 girls by Lee et al found that increased BMI at age 3 years and the rate of increase in BMI from age 3-6 years were both positively associated with an earlier onset of puberty.12

More on Precocious Puberty

Overview: Precocious Puberty
Differential Diagnoses & Workup: Precocious Puberty
Treatment & Medication: Precocious Puberty
Follow-up: Precocious Puberty
Multimedia: Precocious Puberty
References

References

  1. Chalumeau M, Chemaitilly W, Trivin C, et al. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics. Jan 2002;109(1):61-7. [Medline][Full Text].

  2. Ng SM, Kumar Y, Cody D, et al. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. May 2003;88(5):414-8; discussion 414-8. [Medline][Full Text].

  3. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. Jun 1969;44(235):291-303. [Medline].

  4. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. Apr 1997;99(4):505-12. [Medline][Full Text].

  5. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. Oct 1999;104(4 Pt 1):936-41. [Medline][Full Text].

  6. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. Oct 2003;24(5):668-93. [Medline][Full Text].

  7. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. Oct 2002;110(4):752-7. [Medline][Full Text].

  8. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child. Feb 1994;70(2):116-8. [Medline].

  9. de Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious puberty suggests autosomal dominant inheritance. J Clin Endocrinol Metab. Apr 2004;89(4):1794-800. [Medline][Full Text].

  10. [Best Evidence] Mamun AA, Hayatbakhsh MR, O'Callaghan M, Williams G, Najman J. Early overweight and pubertal maturation--pathways of association with young adults' overweight: a longitudinal study. Int J Obes (Lond). Jan 2009;33(1):14-20. [Medline].

  11. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. Sep 13 1974;185(4155):949-51. [Medline].

  12. Lee JM, Appugliese D, Kaciroti N, et al. Weight status in young girls and the onset of puberty. Pediatrics. Mar 2007;119(3):e624-30. [Medline].

  13. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab. Apr 2007;92(4):1424-9. [Medline].

  14. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. Apr 2009;123(4):e752-62. [Medline].

  15. Walvoord EC, Mazur T. Behavioral problems and idiopathic central precocious puberty: Fact or fiction?. Pediatr Endocrinol Rev. June 2007;4 (suppl 3):306-12.

  16. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. Sep 2007;92(9):3483-9. [Medline].

  17. [Guideline] American Academy of Pediatrics. Sexuality education for children and adolescents: Committee on Psychosocial Aspects of Child and Family Health and Committee on Adolescence. Pediatrics. Aug 2001;108(2):498-502.

  18. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. May 2006;91(5):1862-7. [Medline].

  19. Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. Sep 2002;87(9):4111-6. [Medline][Full Text].

  20. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. May 2007;92(5):1697-704. [Medline].

  21. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab. Aug 2004;89(8):3644-50. [Medline][Full Text].

  22. Kaplowitz P. Precocious puberty: update on secular trends, definitions, diagnosis, and treatment. Adv Pediatr. 2004;51:37-62. [Medline].

  23. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. Aug 2001;108(2):347-53. [Medline][Full Text].

  24. Kletter GB, Kelch RP. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. Aug 1994;79(2):331-4. [Medline].

  25. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med. Apr 1994;148(4):369-76. [Medline].

  26. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. Jul 1995;127(1):47-52. [Medline].

  27. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. Jan 1986;108(1):47-54. [Medline].

  28. Reiter EO, Saenger P. Premature adrenarche. The Endocrinologist. 1997;7:85-88.

Further Reading

Keywords

precocious puberty, early puberty, central precocious puberty, CPP, premature thelarche, premature pubarche, precocious pseudopuberty, hyperovarianism, early onset of puberty, sexual precocity, precocious puberty, idiopathic CPP, inappropriate sexual behaviors, increased masturbation, short stature, breast enlargement, clitoral enlargement, enlarged testes, congenital adrenal hyperplasia, familial male precocious puberty, Leydig-cell tumors, HCG-secreting tumors, premature adrenarche, increased body fat, astrocytomas, gliomas, germ cell tumors secreting human chorionic gonadotropin, germ cell tumors secreting HCG, hypothalamic hamartomas, hydrocephalus, arachnoid cysts, suprasellar cysts, treatment, diagnosis

Contributor Information and Disclosures

Author

Paul B Kaplowitz, MD, PhD, Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center
Paul B Kaplowitz, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Indevus Consulting fee Review panel membership

Medical Editor

Phyllis W Speiser, MD, Chief of Pediatric Endocrinology, Schneider Children's Hospital; Professor of Pediatrics, New York University School of Medicine
Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Lynne Lipton Levitsky, MD, Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor, Department of Pediatrics, Harvard University Medical School
Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds PI, also occasional consultant

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.